Macrogenics (MGNX) Return on Capital Employed (2013 - 2026)
Macrogenics (MGNX) reported Return on Capital Employed of 45.01% for Q1 2026, up 798.0% year-over-year from 5.01% in Q1 2025, and down 36.38% quarter-over-quarter from 33.01% in Q4 2025.
Macrogenics (MGNX) Return on Capital Employed (2013 - 2026) Analysis & Trends
Macrogenics (MGNX) has 14 years of Return on Capital Employed data on file, last reported at 45.01% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 45.01%, up 798.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 45.01% (up 798.0% YoY), and the FY2025 annual result was 33.7%, up 1555.0% from the prior year.
- Return on Capital Employed slipped to 45.01% in Q1 2026 per MGNX's latest filing, from 33.01% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 33.01% in Q4 2025 and troughed at 122.34% in Q3 2022.
- A 5-year average of 65.07% and a median of 53.28% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 8296 bps in 2023, then slumped 8349 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 64.14% in 2022, then rose by 0 bps to 63.95% in 2023, then grew by 17 bps to 53.28% in 2024, then jumped by 38 bps to 33.01% in 2025, then plunged by 36 bps to 45.01% in 2026.
- Business Quant data shows MGNX's Return on Capital Employed at 45.01% in Q1 2026, 33.01% in Q4 2025, and 53.17% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -45.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.01% |
| Dec 31, 2025 | -33.01% |
| Sep 30, 2025 | -53.17% |
| Jun 30, 2025 | -39.81% |
| Mar 31, 2025 | -52.99% |
| Dec 31, 2024 | -53.28% |
| Sep 30, 2024 | -61.72% |
| Jun 30, 2024 | -117.97% |
| Mar 31, 2024 | -84.37% |
| Dec 31, 2023 | -63.95% |
| Sep 30, 2023 | -39.37% |
| Jun 30, 2023 | -34.49% |
| Mar 31, 2023 | -34.99% |
| Dec 31, 2022 | -64.14% |
| Sep 30, 2022 | -122.34% |
| Jun 30, 2022 | -113.31% |
| Mar 31, 2022 | -92.34% |
| Dec 31, 2021 | -70.14% |
| Sep 30, 2021 | -43.13% |
| Jun 30, 2021 | -36.00% |